KRAS and non-small cell lung carcinoma: Together, our data suggest that compound 2 has a higher selectivity for the growth inhibition of K-Ras-dependent PDAC and NSCLC, and that the compound may disrupt the kinome reprogramming, resulting in elevated ERK phosphorylation, but blocks ppERK activity.